1.83
-0.025(-1.35%)
Currency In USD
| Previous Close | 1.85 |
| Open | 1.88 |
| Day High | 1.92 |
| Day Low | 1.82 |
| 52-Week High | 12.85 |
| 52-Week Low | 0.87 |
| Volume | 590,006 |
| Average Volume | 2.12M |
| Market Cap | 58.36M |
| PE | -0.45 |
| EPS | -4.06 |
| Moving Average 50 Days | 2.26 |
| Moving Average 200 Days | 5.86 |
| Change | -0.03 |
If you invested $1000 in Outlook Therapeutics, Inc. (OTLK) since IPO date, it would be worth $2.67 as of February 05, 2025 at a share price of $1.825. Whereas If you bought $1000 worth of Outlook Therapeutics, Inc. (OTLK) shares 5 years ago, it would be worth $94.22 as of February 05, 2025 at a share price of $1.825.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors
GlobeNewswire Inc.
Jan 31, 2025 1:05 PM GMT
ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophth
Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD
GlobeNewswire Inc.
Jan 23, 2025 2:05 PM GMT
Data presented at Hawaiian Eye and Retina 2025 MeetingResults confirmed that intravitreal ONS-5010 provided early and sustained anatomic improvements, with steady gains in BCVA and reliable, consistent safetyONS-5010 demonstrated to be non-inferior t
Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
GlobeNewswire Inc.
Jan 22, 2025 2:05 PM GMT
Live webcast on Wednesday, January 29th at 2:00 PM ETISELIN, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United